S&P 500   3,339.87 (-0.99%)
DOW   28,957.54 (-0.90%)
QQQ   231.58 (-1.36%)
AAPL   316.25 (-1.26%)
FB   210.76 (-1.78%)
MSFT   180.49 (-2.13%)
GOOGL   1,502.30 (-0.97%)
CGC   22.05 (-1.17%)
BABA   213.76 (-1.96%)
GE   12.31 (-1.76%)
TSLA   891.01 (-0.93%)
AMD   55.18 (-3.65%)
ACB   1.66 (-1.19%)
F   7.94 (-1.12%)
PRI   132.19 (-3.09%)
BAC   34.27 (-1.69%)
GILD   68.87 (+2.79%)
S&P 500   3,339.87 (-0.99%)
DOW   28,957.54 (-0.90%)
QQQ   231.58 (-1.36%)
AAPL   316.25 (-1.26%)
FB   210.76 (-1.78%)
MSFT   180.49 (-2.13%)
GOOGL   1,502.30 (-0.97%)
CGC   22.05 (-1.17%)
BABA   213.76 (-1.96%)
GE   12.31 (-1.76%)
TSLA   891.01 (-0.93%)
AMD   55.18 (-3.65%)
ACB   1.66 (-1.19%)
F   7.94 (-1.12%)
PRI   132.19 (-3.09%)
BAC   34.27 (-1.69%)
GILD   68.87 (+2.79%)
S&P 500   3,339.87 (-0.99%)
DOW   28,957.54 (-0.90%)
QQQ   231.58 (-1.36%)
AAPL   316.25 (-1.26%)
FB   210.76 (-1.78%)
MSFT   180.49 (-2.13%)
GOOGL   1,502.30 (-0.97%)
CGC   22.05 (-1.17%)
BABA   213.76 (-1.96%)
GE   12.31 (-1.76%)
TSLA   891.01 (-0.93%)
AMD   55.18 (-3.65%)
ACB   1.66 (-1.19%)
F   7.94 (-1.12%)
PRI   132.19 (-3.09%)
BAC   34.27 (-1.69%)
GILD   68.87 (+2.79%)
S&P 500   3,339.87 (-0.99%)
DOW   28,957.54 (-0.90%)
QQQ   231.58 (-1.36%)
AAPL   316.25 (-1.26%)
FB   210.76 (-1.78%)
MSFT   180.49 (-2.13%)
GOOGL   1,502.30 (-0.97%)
CGC   22.05 (-1.17%)
BABA   213.76 (-1.96%)
GE   12.31 (-1.76%)
TSLA   891.01 (-0.93%)
AMD   55.18 (-3.65%)
ACB   1.66 (-1.19%)
F   7.94 (-1.12%)
PRI   132.19 (-3.09%)
BAC   34.27 (-1.69%)
GILD   68.87 (+2.79%)
Log in

NASDAQ:VTVT - vTv Therapeutics Stock Price, Forecast & News

$3.21
+0.28 (+9.57 %)
(As of 02/21/2020 11:12 AM ET)
Today's Range
$2.97
Now: $3.21
$3.37
50-Day Range
$1.77
MA: $2.31
$3.20
52-Week Range
$1.23
Now: $3.21
$4.23
Volume1.43 million shs
Average Volume1.61 million shs
Market Capitalization$173.50 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.55
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.43 million
Book Value($1.91) per share

Profitability

Net Income$-7,910,000.00
Net Margins-140.72%

Miscellaneous

Employees52
Market Cap$173.50 million
Next Earnings Date5/6/2020 (Estimated)
OptionableNot Optionable

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.


vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.06. The biotechnology company had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.06 million. View vTv Therapeutics' Earnings History.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for vTv Therapeutics.

What price target have analysts set for VTVT?

2 brokerages have issued 1 year target prices for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate vTv Therapeutics' share price to reach $7.00 in the next year. This suggests a possible upside of 119.4% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.

What is the consensus analysts' recommendation for vTv Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for vTv Therapeutics.

What are Wall Street analysts saying about vTv Therapeutics stock?

Here are some recent quotes from research analysts about vTv Therapeutics stock:
  • 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (2/14/2020)
  • 2. HC Wainwright analysts commented, "Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success." (8/16/2019)

Has vTv Therapeutics been receiving favorable news coverage?

News stories about VTVT stock have trended negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. vTv Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for vTv Therapeutics.

Who are some of vTv Therapeutics' key competitors?

What other stocks do shareholders of vTv Therapeutics own?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of America Corp DE (0.24%), Barclays PLC (0.24%) and Renaissance Technologies LLC (0.07%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Which major investors are buying vTv Therapeutics stock?

VTVT stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $3.19.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $172.67 million and generates $12.43 million in revenue each year. The biotechnology company earns $-7,910,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.View Additional Information About vTv Therapeutics.

What is vTv Therapeutics' official website?

The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel